BioVentrix (BVXX) investor relations material

Company overview and business model

• Focuses on developing, manufacturing, and commercializing proprietary devices to restore left ventricular function in heart failure patients with reduced ejection fraction (HFrEF), with the Revivent System as the lead product.

• Revivent System is CE-marked in Europe and in pivotal U.S. trial; targets patients with severe anterior wall scarring post-STEMI.

• Also owns Alginate, a hydrogel-based device for HFrEF patients without anterior scarring, with plans for future clinical development.

• Business model centers on clinical validation, regulatory approval, and targeted commercialization, with a focus on high-volume, high-value surgical procedures for cardiac surgeons.

Financial performance and metrics

• Reported net losses of $7.7 million in 2025 and $3.9 million in 2024, with an accumulated deficit of $231.2 million as of December 31, 2025.

• Cash balance was $1.8 million at year-end 2025; working capital deficit of $11.6 million.

• Research and development expenses increased 99% to $1.17 million in 2025, and selling, general, and administrative expenses rose 71% to $5.1 million.

• Operations have been primarily financed through private equity and convertible debt; substantial doubt exists about ability to continue as a going concern without additional capital.

Use of proceeds and capital allocation

• Approximately 60% of net proceeds from the IPO will fund the pivotal RELIVE clinical trial and associated manufacturing activities.

• Remaining 40% allocated to working capital, regulatory compliance, intellectual property protection, and general corporate purposes.

• Management retains broad discretion over use of proceeds and may adjust allocations as needed.